Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Blood

Volumn 128, Issue 1, 2016, Pages 34-44

  Usmani, Saad Z ^a   Weiss, Brendan M ^b   Plesner, Torben ^c   Bahlis, Nizar J ^d   Belch, Andrew ^e   Lonial, Sagar ^f   Lokhorst, Henk M ^g   Voorhees, Peter M ^h   Richardson, Paul G ⁱ   Chari, Ajai ^j   Sasser, A Kate ^k   Axel, Amy ^k   Feng, Huaibao ^l   Uhlar, Clarissa M ^k   Wang, Jianping ^k   Khan, Imran ^l   Ahmadi, Tahamtan ^k   Nahi, Hareth ^m  

^a LEVINE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF CALGARY   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^l LLC   (United States)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ALLERGIC RHINITIS; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; BRONCHOSPASM; CHILL; CLINICAL EFFECTIVENESS; COUGHING; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GENDER; GEOGRAPHY; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OVERALL SURVIVAL; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE; RELAPSE; THROAT IRRITATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; REMISSION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84977616350     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-705210     Document Type: Article

References (26)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
2. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23(6): 1152-1157.
3. Usmani S, Ahmadi T, Ng Y, Lam A, Potluri R, Mehra M. Analyses of real world data on overall survival in multiple myeloma patients with at least 3 prior lines of therapy including a PI and an IMiD, or double refractory to a PI and an IMiD [abstract]. Blood. 2015;126(23). Abstract 4498.
4. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
5. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-321.
6. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]. Blood. 2014;124(21). Abstract 3474.
7. Deaglio S, Mehta K, Malavasi F. Human CD38: A (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1-12.
8. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482-488.
9. Santonocito AM, Consoli U, Bagnato S, et al. Flow cytometric detection of aneuploid CD38(11) plasmacells and CD19(1) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28(5): 469-477.
10. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immuneregulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma [published online ahead of print May 24, 2016]. Blood. doi:10.1182/blood-2015-12-687749.
11. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13): 1207-1219.
12. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
13. McKeage K. Daratumumab: First Global Approval. Drugs. 2016;76(2):275-281.
14. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015; 55(6 Pt 2):1545-1554.
15. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015; 55(6 Pt 2):1555-1562.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
17. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with lowdose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. Blood. 2014;123(12):1826-1832.
18. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-2825.
19. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009;114(4):772-778.
20. Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9): 1820-1823.
21. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552-559.
22. Ludwig H, Masszi T, Petrucci MT, et al. Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractroy multiple myeloma (RRMM): Results from a phase 3 study (FOCUS) [abstract]. Ann Oncol. 2014;25(Supplement 5). Abstract LBA28.
23. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11): 1055-1066.
24. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-2028.
25. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26): 2455-2465.
26. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.